Star Scientific - 2008 annual report/Stonewall vs other OTC NRTs..

March 18, 2009 - Annual Report 2008 - The company reported 2008 net sales of $0.5 million, which essentially were unchanged from net sales for 2007. However, volume sales of the company's two dissolvable smokeless tobacco products, Ariva® and Stonewall®, increased 7.8% in 2008 compared to 2007. Star reported a net loss for 2008 of $18.3 million compared to the 2007 net loss of $41.5 million.

As the company noted in a January 6, 2009 press release (Star Scientific Corporate Study Stonewall Lozenge in NRT.., its Rock Creek Pharmaceuticals subsidiary recently completed a study to determine the ability of Stonewall® dissolvable smokeless tobacco to relieve cigarette withdrawal symptoms when compared to an over-the-counter nicotine replacement product (NRT). Rock Creek applied to have the study results included in an abstract submission at the Society for Research in Nicotine and Tobacco (SRNT) -- Europe Conference to be held in Dublin, Ireland in April 2009, and was recently notified that the submission has been accepted. An abstract on lung cancer death rates that previously had been submitted and accepted also will be presented by Rock Creek at the conference.

Some related Star Scientific News briefs: Star Scientific Corporate Study Stonewall Lozenge in NRT..; Star Scientific Files Third Quarter Financial Report..; Star Scientific wants to augment sales of their tobacco lozenges..; Star Scientific , second quarter 2008, sales down 23.6%..;Star Scientific Applauds Recent State Legislation - Banning Smoking in Cars with Children..

Reference: Star Scientific Files Annual Financial Report, Star Scientific Inc., 3/16/2009.